Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review

To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF

“…List of abbreviations: JIA: juvenile idiopathic arthritis, m months, IFX infliximab, ADA adalimumab, ABA abatacept, TOC tocilizumab, MTX methotrexate, MMF mycophenolate mofetil, RTX rituximab, GOL golimumab, AZA Azathioprine, LEF leflunomide, CSA cyclosporine, N number, CCS corticosteroid, F-up follow-up, pts patients. First Author and year of publication, study design F-up (range) months N of pts N of pts for each disease N of female Median age at drug start (range), months Median age at onset uveitis (range), months Drug Concomitant therapy Uveitis activity (Descriptive) N of pts who achieve remission Time to achieve remission, months N of pts with stable visual acuity N of pts with normal visual acuity N of pts with improved visual acuity Worsening of Visual acuity n of pts who reduced systemic ccs N of pts who stopped local ccs Duration of inactivity, Months N of pts with relapse Adverse event drug Ashkenazy N et al, 2019, Retrospective 21 [ [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] ] 12 7 Idiopathic, 1 Sarcoidosis, 4 JIA 8 125 (96–192) IFX 10 MTX 2 MMF 12 initial response to IFX 8/12 8,6 m [ [1] ...…”

“…Consequently, for those patients who fail the initial anti-TNFα, exploring alternative treatment strategies considering a non-anti-TNFα, of note to swap, or resorting to a second anti-TNFα, technically to switch using a drug belonging to the same family, may be warranted [ [10] , [11] , [12] , [13] , [9] ].…”

New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview

“…Furthermore, new insights have emerged to present new therapeutic approaches directed against immune components as potential novel therapies for NIU. Case report (Simonini et al, 2013b) Systematic review (Simonini et al, 2015) Anakinra IL-1 receptor antagonist Systematic review (Simonini et al, 2015) Rituximab Anti CD20 antibody Systematic review (Simonini et al, 2015) Retrospective study (Miserocchi et al, 2016) Clinical trial (Davatchi et al, 2010) IL, interleukin; CD, cluster of differentiation.…”

Konventionelle synthetische Immunsuppressiva (DMARDs) für die Therapie der nichtinfektiösen Uveitis

“…In der umfangreichen retrospektiven SITE-Studie (SITE: "Systemic Immunosuppressive Treatment for Eye Diseases") wurde die Effektivität der einzelnen csDMARDs standardisiert erhoben [9 -11], und es können Empfehlungen zur Verwendung von DMARDs in der täglichen Praxis abgeleitet werden. Im folgenden Abschnitt wird ein Überblick über die einzelnen csDMARDs gegeben [3,8,12,13 einer Kombinationstherapie Adalimumab und Methotrexat behandelt werden, die 10-mg-MTX-Dosierung ausreichend ist [26]. Patienten unter csDMARD-Therapie müssen gemeinsam von Ophthalmologen und Internisten (insbesondere Rheumatologen) betreut und überwacht werden.…”